PMID- 21617239
OWN - NLM
STAT- MEDLINE
DCOM- 20110829
LR  - 20181201
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 31
IP  - 5
DP  - 2011 May
TI  - Bevacizumab in first-line therapy of metastatic colorectal cancer: a 
      retrospective comparison of FOLFIRI and XELIRI.
PG  - 1777-82
AB  - BACKGROUND: The antivascular endothelial growth factor monoclonal antibody 
      bevacizumab with infusional 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) 
      is a standard first-line treatment option for metastatic colorectal cancer. 
      However, clinical data for capecitabine and irinotecan (XELIRI) with bevacizumab 
      are limited. PATIENTS AND METHODS: A retrospective study was conducted on 139 
      patients with metastatic colorectal cancer to assess the efficacy and safety of 
      first-line bevacizumab in combination with XELIRI or FOLFIRI. Primary endpoints 
      were overall response rate (ORR), disease control rate and radical resection 
      rate. Secondary endpoints included overall survival (OS), progression-free 
      survival (PFS) and safety. RESULTS: No significant differences in efficacy were 
      observed between patients administered XELIRI or FOLFIRI with bevacizumab. The 
      ORR, median OS and PFS and recorded adverse events (AEs) were comparable to those 
      previously reported, with no new or unexpected AEs observed. CONCLUSION: 
      Bevacizumab is similarly efficacious and well tolerated when administered with 
      XELIRI or FOLFIRI.
FAU - Ocvirk, Janja
AU  - Ocvirk J
AD  - Department of Medical Oncology, Institute of Oncology Ljubljana, Slovenia. 
      jocvirk@onko-i.si
FAU - Rebersek, Martina
AU  - Rebersek M
FAU - Boc, Marko
AU  - Boc M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - 7673326042 (Irinotecan)
RN  - Q573I9DVLP (Leucovorin)
RN  - U3P01618RT (Fluorouracil)
RN  - XT3Z54Z28A (Camptothecin)
RN  - IFL protocol
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bevacizumab
MH  - Camptothecin/administration & dosage/analogs & derivatives/therapeutic use
MH  - Capecitabine
MH  - Colorectal Neoplasms/*drug therapy/pathology
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Disease Progression
MH  - Female
MH  - Fluorouracil/administration & dosage/analogs & derivatives/therapeutic use
MH  - Humans
MH  - Irinotecan
MH  - Leucovorin/therapeutic use
MH  - Liver Neoplasms/*drug therapy/secondary
MH  - Lung Neoplasms/*drug therapy/secondary
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
EDAT- 2011/05/28 06:00
MHDA- 2011/08/30 06:00
CRDT- 2011/05/28 06:00
PHST- 2011/05/28 06:00 [entrez]
PHST- 2011/05/28 06:00 [pubmed]
PHST- 2011/08/30 06:00 [medline]
AID - 31/5/1777 [pii]
PST - ppublish
SO  - Anticancer Res. 2011 May;31(5):1777-82.